Last reviewed · How we verify
Diclofenac Capsules high dose
Diclofenac works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins, leading to reduced inflammation and pain.
Diclofenac works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins, leading to reduced inflammation and pain. Used for Osteoarthritis, Rheumatoid arthritis, Ankylosing spondylitis.
At a glance
| Generic name | Diclofenac Capsules high dose |
|---|---|
| Sponsor | Iroko Pharmaceuticals, LLC |
| Drug class | NSAID |
| Target | COX-2 |
| Modality | Small molecule |
| Therapeutic area | Rheumatology |
| Phase | Phase 2 |
Mechanism of action
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2, an enzyme responsible for the production of prostaglandins, which are mediators of inflammation and pain. By inhibiting COX-2, diclofenac reduces the production of prostaglandins, leading to decreased inflammation and pain. This mechanism of action is responsible for the therapeutic effects of diclofenac in treating conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
Approved indications
- Osteoarthritis
- Rheumatoid arthritis
- Ankylosing spondylitis
Common side effects
- Gastrointestinal upset
- Headache
- Dizziness
Key clinical trials
- Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diclofenac Capsules high dose CI brief — competitive landscape report
- Diclofenac Capsules high dose updates RSS · CI watch RSS
- Iroko Pharmaceuticals, LLC portfolio CI